Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Prostatic Neoplasms 83Neoplasm Metastasis 9Prostatic Neoplasms, Castration-Resistant 5Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Castration-resistant Prostate Cancer 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thrombocytosis 1Prostatic Diseases 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Ovarian Neoplasms 1

Interventions

pertuzumab 3trametinib 2palbociclib 2dabrafenib 2copanlisib 2Trastuzumab 2Sunitinib 2Specimen Handling 2Sorafenib 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Immunoglobulin G 2HhAntag691 2Fluorouracil 2Disulfides 2Dasatinib 2Bevacizumab 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2venetoclax 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1sapanisertib 1ruxolitinib 1romidepsin 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × abiraterone × Genitourinary × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡